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Germline mutations in breast cancer susceptibility genes BRCA1
and BRCA2 account for the majority of families with hereditary
breast and ovarian cancers (Easton et al, 1993; Miki et al, 1994;
Wooster et al, 1995; Tavtigian et al, 1996). Carriers of these muta-
tions have an increased life-time risk of developing breast and
ovarian cancers (Ford et al, 1994; Berman et al, 1996; Phelan et al,
1996). Both genes are large and multi-exonic: the coding region of
BRCA1 contains 5592 base pairs distributed over 22 coding exons
and BRCA2 contains 10 254 base pairs of coding sequence within
26 exons (Miki et al, 1994; Tavtigian et al, 1996). To date, more
than 500 distinct sequence alterations distributed throughout the
coding region have been described in each gene (Couch and
Weber, 1996; Breast Cancer Information Core, 1999). Therefore,
BRCA mutation analysis is hampered by the large size of the
genes and by the diversity of multiple distinct mutations.
According to Turkish statistics, the breast cancer incidence in
Turkey in 1994 was 6.14 per 100 000. In that year breast cancer
constituted 23.04% of all cancers, representing the most common
type of cancer in Turkish women (Turkish Ministry of Health,
1994). Founder mutations of both BRCA1 and BRCA2 have been
described for several ethnic or geographically isolated populations
(Szabo and King, 1997). The majority of hereditary breast cancer
families of Ashkenazi Jewish ancestry are due to a restricted
number of BRCA mutations (185delAG and 5382insC in BRCA1
and 6174delT in BRCA2) (Abeliovich et al, 1997; Levy-Lahad et
al, 1997). In 24% of Icelandic women with familial breast cancer,
a single mutation in the BRCA2 gene (999del5) is observed
(Johannesdottir et al, 1996). The presence of founder mutations in
a population simplifies the identification of those with inherited
susceptibility to breast and ovarian cancer. This will facilitate both
the development of hereditary cancer research and the clinical
application of genetic testing for the population studied.
Studies on the BRCA1 and BRCA2 genes in the Turkish popu-
lation have not been published and the spectrum of mutations is
not known. In this study we report our observations of the frequen-
cies and types of BRCA1 and BRCA2 mutations in a group of
Turkish breast and/or ovarian cancer patients with and without a
family history of cancer.
MATERIALS AND METHODS
Peripheral blood specimens
We recruited 53 patients with a family history of breast and/or
ovarian cancers, and 52 early-onset breast cancer cases below age 50
without a family history of cancer. These patients were referred to the
Istanbul University Oncology Institute and the Department of
Surgery of the Istanbul Medical Faculty. Families were selected from
consecutive referrals to the above-listed hospitals meeting specific
family-history criteria (either multiple cases of breast and or ovarian
cancer or the presence of an individual with a young age at diag-
nosis). Blood samples were obtained from all patients and genomic
DNA was extracted using the phenol/chloroform extraction method.
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All samples were initially analysed for exon 11 mutations of both
BRCA1 and BRCA2 using the protein truncation test (PTT) as
described previously (Ozcelik et al, 1996; 1997). The PTT
analysis was restricted to the analysis of exon 11 of each gene
since cellular RNA samples were not available from these patients.
Exon 10 of BRCA2 was also analysed by using protein truncation
test as described (Hakansson et al, 1997).
Sequencing analysis
Sequencing analysis of BRCA1 gene was carried out by auto-
mated sequencing (ABI, Foster City, CA, USA). The primer
sequence information was obtained from the primer database
(Breast Cancer Information Core, 1999) and the sequencing was
carried out according to the company protocols.
Heteroduplex analysis
Heteroduplex analysis was carried out for exons 2, 14 and 20 of
the BRCA1 gene. PCR products from exons 2 (160 bp), 14 (236
bp) and exon 20 (120 bp) were amplified using the following
primers: Exon 2, forward 5′ -CTTCGCGTTGAAGAAGTAC-3′
and reverse 5′ -GTCTTTTCTTCCCTAGTATGT-3′ ; Exon 14,
forward 5′ -CTAACCTGAATTATCACTATCA-3′ and reverse 
5′ -AAGATGTCAGATACCACAGC-3′ ; and exon 20, forward 
5′ -TGGAAGAAACCACCAAGGTC- 3′ , reverse 5′ -GGGGAG
TGGAATACAGAGTGGT-3′ .
PCR reactions for all three exons were carried out in a 50 µ l
reaction volume containing 1 × PCR buffer (10 mM Tris-HCl (pH
8.3), 50 mM KCl, 0.01% Gelatin), 3 mM MgCl2, 112.5 mM of
each deoxyribonucleoside triphosphate (dNTP), 10 pmol of each
primer, 1 U of AmpliTaq DNA polymerase (Perkin Elmer/Cetus,
Foster City, CA, USA) and 200 ng of genomic DNA. The PCR
reaction was carried out for 30 cycles. The thermal cycling condi-
tions were 94° C for 30 s, 55° C for 30 s and 72° C for 1 min.
Heteroduplex analyses were carried out using 1 × MDE (FMC
BioProducts, Maine, USA) gel system for all three exons. The
electrophoresis was performed at 70 V overnight in 0.6 × TBE (89
mM Tris-base, 89 mM Boric Acid, 2 mM EDTA pH 8.0) buffer.
The results were visualized under UV-transilluminator.
RESULTS
BRCA1 and BRCA2 mutational analysis
We investigated the presence of BRCA1 and BRCA2 mutations in
53 patients with a personal and family history of breast and/or
ovarian cancers, and 52 breast cancer patients below age 50. All
samples were initially analysed for exon 11 mutations in both
BRCA1 and BRCA2 and exon 10 in BRCA2 using the protein
truncation test. The PTT analysis was restricted to the exons noted
above, as cellular RNA samples were not available from these
patients. We identified six truncating mutations in exons 11 (four
BRCA1 and two BRCA2) of the 105 patients studied (Figure 1A,
B) No mutations were found in exon 10 of BRCA2 (Table 1).
The remaining exons of the BRCA1 gene were also sequenced
in a subset of 24 patients. Families were selected from three cate-
gories of family history: families with multiple breast cancers,
families with multiple breast and ovarian cancers, and families
with only early-onset breast cancer. The first consecutive 14, five
and five patients were selected from the above categories, respec-
tively. We identified two additional mutations outside exon 11 of
BRCA1: insertion of a ‘C’ in exon 20 (5382insC), and deletion of
a ‘G’ at the first nucleotide of intron 14 (IVS-14+1delG). The
latter mutation resulted in the skipping of exon 14 during splicing,
leading to a frameshift in the reading frame, and premature termi-
nation of the protein.
Heteroduplex analysis was performed to specifically investigate
the presence of BRCA1 5382insC and IVS-14+1delG mutations in
the rest of the samples not sequenced for the entire BRCA1 coding
region. An additional 5382insC mutation was identified in a
patient (Figure 2A). We did not detect additional IVS-14+1delG
mutations, however the exon 14 heteroduplex analysis revealed a
novel 4508delG BRCA1 mutation (Figure 2B). Since the
5382insC mutation is one of the common Ashkenazi Jewish muta-
tions, we have also looked for the exon 2, 185delAG mutation in
our families. Although no del185AG mutations were identified,
the exon 2 heteroduplex analysis did detect a single 185insA muta-
tion (Figure 2C).
Distribution of mutations in groups
Using the approach described above, a total of 11 mutations (nine
BRCA1 and two BRCA2) were identified in the 105 samples
studied (Table 1). We found 15.1% (8/53) of Turkish patients with
a family history of breast and/or ovarian cancer to have BRCA1
and BRCA2 mutations (Table 2). Three (two BRCA1 and one
BRCA2) mutations were observed in families with three or more
breast cancer cases with at least two in a first-degree relationship.
Only one BRCA1 mutation was found in 34 families with two
cases of breast cancer in a first or second-degree relationship. Four
BRCA1 mutations were found in ten families with breast and
ovarian cancer.
We also studied 52 breast cancer patients diagnosed between the
ages of 20 and 50 years without additional cancer history. Among
these 52, 28 cases were between ages 20 and 35, and 24 cases were
between 36 and 50. The average age of this group was 34.46 ±
7.26. Three of the 52 (5.8%) were found to carry BRCA mutations
(Table 2). Two of the mutations were in BRCA1 and one was in
BRCA2. The patients carrying these mutations were 37 (BRCA1),
38 (BRCA1) and 40 (BRCA2) years old, respectively.
DISCUSSION
In this study BRCA1 and BRCA2 mutations were investigated in
Turkish breast and ovarian cancer patients using combined tech-
niques. Among 53 cases with a family history of breast and/or
ovarian cancers, we have detected seven BRCA1 and one BRCA2
mutations. The presence of a mutation was related to the strength
of the family history of breast and ovarian cancer. Forty percent of
families with ovarian cancer with or without family history of
breast cancer and 33% of families with three or more breast cancer
cases in a first or second-degree relationship were found to carry
BRCA mutations (Table 2). However, only 3% of families with
two cases of breast cancer in close relatives were found to harbour
BRCA mutations. This experience is similar to other international
groups attempting to find BRCA mutations in breast and ovarian
cancer families (Couch et al, 1997; Ford et al, 1998).
Mutational analysis was also performed on 52 women 
with breast cancer diagnosed under the age of fifty, who had no
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 identifiable family history of cancer. This approach allowed us to
determine whether or not early age at diagnosis, in the absence of
additional family history of cancer, is a determinant of inherited
susceptibility. Three of 52 (5.8%) women in this group were found
to carry BRCA mutations. Two BRCA1 mutations were observed
in patients at the age of 37 and 38, respectively. The patient with
the BRCA2 mutation had breast cancer diagnosed at age 40. No
mutations were identified in 28 women diagnosed before the age
of 35. However, the difference in the distribution of mutations
between the two age-groups may not be significant due to the
740 H Yazici et al
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Figure 1 (B) Identification of BRCA exon 11 mutations PTT and
sequencing analysis of exon 11 of BRCA2. Top panel shows the two BRCA2
mutations detected in exon 11 of cases F9 and F60. Lower panel shows the
actual location of mutations (indicated by an arrow).
Table 1 BRCA1 and BRCA2 mutations detected in Turkish individuals
Family No. Type of Cancer Exon Mutation Effect Fhx BIC
BRCA1 mutations
98 Breast 11 1623delTTAAA Frameshift No Yes
137 Breast 11 2139delC Frameshift Yes Yes
1 Breast 11 3819delGTAAA Frameshift Yes Yes
154 Ovary 11 2476delT Frameshift Yes No
51 Breast 14 4508delC Frameshift Yes No
142 Breast Int 14 IVS-14+1delG Splice Error Yes No
49 Ovary 20 5382insC Frameshift Yes Yes
65 Breast 20 5382insC Frameshift No Yes
147 Breast 2 185insA Frameshift Yes Yes
BRCA2 mutations
60 Breast 11 5295insA Frameshift No No
9 Breast 11 6656delC Frameshift Yes No
5382insC
M
4508delC IVS14+1delG
M
185insA 185delAG
M
 A
 B Exon 14
C Exon 2
Exon 20
Figure 2 Heteroduplex analysis of three exons of BRCA1. Gel
electrophoresis for all exons are performed using MDE gel system. An arrow
indicates positive cases and the mutation type is indicated on the top. (A)
Heteroduplex analysis of exon 20. One of the cases with the 5382insC
mutation represents a positive control. (B) Heteroduplex analysis of exon 14.
The IVS-14+1delG mutation is used as a positive control. (C) Heteroduplex
analysis of exon 2. The 185delAG mutation is used as a positive control. M =
DNA marker
Bsmall sample size. The presence of BRCA mutations in a popula-
tion of women with early-onset breast cancer, without a cancer
family history, has also been documented in other studies
(Langston et al, 1996; Southey et al, 1999). Our observations
support the notion that individuals with early-onset breast cancer,
without family history, should also be considered candidates at
risk for inherited susceptibility to breast and ovarian cancer in the
Turkish population.
Five mutations detected in this study have not previously been
reported in the Breast Cancer Information Core Database (Table
1). The remaining mutations have been reported in individuals of
German, Spanish, Dutch, Belgian, Russian and Jewish ethnic
background (Breast Cancer Information Core, 1999). This
suggests that the mutations detected in this population are influ-
enced by the ethnic admixture and the geographical location of the
population studied. Accordingly, genetic admixture of β -globin
gene mutations between Turkey and other neighbouring countries
has been already demonstrated (Tadmouri et al, 1998).
The only mutation detected twice in our study population was
the BRCA1 5382insC mutation. The same type of BRCA1 muta-
tion has been demonstrated to occur repeatedly in the Ashkenazi
Jewish and Russian populations due to founder effect (Abeliovich
et al, 1997; Gayther et al, 1997; Levy-Lahad et al, 1997; Csokay et
al, 1999). Haplotype analysis would help to determine if these
mutations found in our cohort were ancestrally related to those
found in other populations.
Identification of BRCA mutations in a substantial proportion of
our patients indicates that these genes play a role in the incidence
of breast cancer in the Turkish population. Due to limitations we
were unable to analyse the entire BRCA coding regions in all the
patients. Exons 10 and 11 of BRCA2 and exon 11 of BRCA1
where analysed in all patients. These exons constitute approxi-
mately 60% of the coding regions of each gene. If a roughly
uniform distribution of mutations throughout both genes exists in
the Turkish population, we would estimate that 60% of protein-
truncating mutations were detected by this approach. We have also
sequenced a subset of cases for the BRCA1 gene and screened the
remaining patients for specific BRCA1 mutations. Therefore, the
BRCA1 analysis is more complete than that for BRCA2 in this
cohort. A more complete analysis of the BRCA genes might yield
an even greater proportion of families with mutations. Due to the
selection of those at a high genetic risk in our cohort, our mutation
frequency may not reflect that of the Turkish breast cancer popula-
tion in general. However, this study demonstrates the presence of
BRCA mutations in families with breast and ovarian cancer and
should be considered an integral element in the management of
disease risk in Turkey.
On the other hand, the families in this study were ascertained
based on the presence of family history or early onset of disease.
The proportion of mutations found in our study population is most
likely an overestimate of the proportion of mutations in the general
Turkish population of breast and ovarian cancer patients. A popu-
lation-based ascertainment scheme would provide the most accu-
rate estimate of this. However, the families in this study may more
accurately represent the types of families that would request, and
more likely benefit from, genetic testing in a research or clinically
based setting.
This is the first study to report the types of BRCA mutations in
the Turkish population. Our results suggest that BRCA1 and
BRCA2 mutations are observed in a significant proportion of
Turkish families with breast and/or ovarian cancer, and those with
early onset of disease. Our study demonstrates the importance of
the consideration of inherited predisposition to breast and ovarian
cancer in the clinical management of breast cancer risk in Turkey.
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